Intrinsic Fibrinolysis and Arterial Thrombosis

Abstract

Get full access to this article

View all access options for this article.

References

1. Rao AK , Sheth S , Kaplan R : Inherited hypercoagulable states. Vasc Med 2:313-320, 1997.

2. Denys J , De Marbaix H : Les peptonisations provoquees par le chloroforme. Cellule 5:197-197, 1889.

3. Dastre A : Fibrinolyse dans le sang. Arch Norm Pathol 5:661-664, 1893.

4. Verstraete M : The fibrinolytic system: From Petri dishes to genetic engineering. Thromb Haemost 74:25-35, 1995.

5. Preissner KT , Kanse SM , Chavakis T , et al: The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: Implications for cardiovascular function. Basic Res Cardiol 94:315-321, 1999.

6. Kannel WB , D'Agostino RB , Belanger AJ , et al: Longterm influence of fibrinogen on initial and recurrent cardiovascular events in men and women. Am J Cardiol 78:90-92, 1996.

7. Kannel WB : Influence of fibrinogen on cardiovascular disease. Drugs 54(suppl 3):32-40, 1997.

8. Ernst E , Resch KL : Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 118:956-963, 1993.

9. de la Serna G : Fibrinogen: A new major risk factor for cardiovascular disease. A review of the literature. J Fam Pract 39:468-477, 1994.

10.

10. Bolibar I , Kienast J , Thompson MA , et al: ECAT Angina Pectoris Study Group. Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. Am Heart J 125:1601-1605, 1993.

11.

11. Handa K , Kono S . Saku K , et al: Plasma fibrinogen level as an indicator of severity of coronary atherosclerosis. Atherosclerosis 77:209-213, 1989.

12.

12. Hamsten A , de Faire U . Walldius G , et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987.

13.

13. Juhan-Vague I , Pyke SDM , Alessi MC , et al: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 94:2057-2063, 1996.

14.

14. Gray RP , Yudkin JS , Patterson DLH : Plasminogen activator inhibitor: A risk factor for myocardial infarction in diabetic subjects. Br Heart J 69:228-232, 1993.

15.

15. Gray RP , Patterson DL , Yudkin JS : Plasminogen activator inhibitor activity in diabetic and non-diabetic survivors of myocardial infarction. Arterioscler Thromb 13:415-420, 1993.

16.

16. Thompson SG , Kienast J , Pyke SDM , et al: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641, 1995.

17.

17. Ranby M , N'Guyen G , Scarabin PY , et al: Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Thromb Haemost 61:409-414, 1989.

18.

18. Chandler WL , Alessi MC , Aillaud MF , et al: Clearance of tissue plasminogen activator (tPA) and tPA/plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated tPA antigen in patients with high PAI-1 activity levels. Circulation 96:761-768, 1997.

19.

19. Fuster V , Verstraete M (eds): Thrombosis in Cardiovascular Disorders. Philadelphia: WB Saunders, 1992, pp 55-61.

20.

20. Ducimetiere P . Eschwege E , Papoz L , et al: Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19:205-210, 1980.

21.

21. Despres J-P , Lamarche B , Mauriege P , et al: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996.

22.

22. Yudkin JS : Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 22(suppl 3):C25-C29, 1999.

23.

23. Juhan-Vague I , Roul C , Alessi C , et al: Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic subjects: Relationship with plasma insulin. Thromb Haemost 61:370-373, 1989.

24.

24. Potter van Loon BJ , Kluft C , Radder JK , et al: The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42:945-949, 1993.

25.

25. Landin K , Tengborn L , Smith U : Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227:273-278, 1990.

26.

26. Juhan-Vague I , Thompson SG , Jespersen J : Involvement of the hemostatic system in the insulin resistance syndrome: A study of 1,500 patients with angina pectoris. Arterioscler Thromb 13:1865-1873, 1993.

27.

27. Dawson SJ , Wiman B , Hamsten A , et al: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268:10739-10745, 1993.

28.

28. Eriksson P , Kallin B , van't Hooft FM , et al: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855, 1995.

29.

29. Panahloo A , Mohamed-Ali V , Lane A , et al: Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 44:37-42, 1995.

30.

30. Ye S , Green FR , Scarabin PY , et al: The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-i (PAI-1) gene is associated with ECTIM study. Thromb Haemost 74:837-841, 1995.

31.

31. Gardemann A , Lohre J , Katz N , et al: The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 82:1121-1126, 1999.

32.

32. Mansfield MW , Stickland JH , Grant PJ : Plasminogen activator-i (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 74:1032-1034, 1995.

33.

33. Ridker PM , Hennekens CH , Lindpaintner K , et al:Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 95:59-62, 1997.

34.

34. Burzotta F . Di Castelnuovo A , Amore C , et al: 4G/5G polymorphism in the promoter region of the PAI-I gene is not a risk factor for familial myocardial infarction: A case-control study in a sample of GISSI-2 patients. Thromb Haemost 78:1294-1295, 1997.

35.

35. lacoviello L , Burzotta F , De Castelnuovo A , et al: The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis. Thromb Haemost 80:1029-1030, 1998.

36.

36. Humphries SE , Cook M , Dubowitz M , et al: Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1:1452-1455, 1987.

37.

37. Berg K , Kierulf P : DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clin Genet 36:229-235, 1989.

38.

38. de Maat MPM , Kastelein JJP , Jukema JW , et al:-455G/A polymorphism of the,B-fibrinogen gene is associated with the progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 18:265-271,1998.

39.

39. Paramo JA , Olavide I , Barba J , et al: Long-term cardiac rehabilitation program favorably influences fibrinolysis and lipid concentrations in acute myocardial infarction. Haematologica 83:519-524, 1998.

40.

40. Lee AJ , Fowkes FGR , Lowe GDO , et al: Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh artery study. Thromb Haemost 81:553-560, 1999.

41.

41. Kannel WB , D'Agostino RB , Belanger AJ : Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 2:457-466, 1992.

42.

42. Wilhelmsen L , Svardsudd K , Korsan-Bengtsen K , et al: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501-505, 1984.

43.

43. Smith FB , Lee AJ , Fowkes FG , et al: Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study. Arterioscler Thromb Vasc Biol 17:3321-3325, 1997.

44.

44. Carter AM , Catto AJ , Grant PJ : Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease. Thromb Haemost 80:632-636, 1998.

45.

45. Mansfield MW , Catto AJ , Carter AM , et al: Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction. Diabet Med 15:953-957,1998.

46.

46. Macko RF , Kittner SJ , Epstein A , et al: Elevated tissue plasminogen activator antigen and stroke risk. The stroke prevention in young women study. Stroke 30:7-11, 1999.

47.

47. Killewich LA , Macko RF , Gardner AW , et al: Defective fibrinolysis occurs after infrainguinal reconstruction. J Vasc Surg 25:858-865, 1997.

48.

48. Killewich LA , Gardner AW , Macko RF , et al: Progressive intermittent claudication is associated with impaired fibrinolysis. J Vasc Surg 27:645-650, 1998.

49.

49. Stratton JR , Chandler WL , Schwartz RS , et al: Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 83:1692-1697, 1991.

50.

50. Lindahl B , Nilsson TK , Jansson JH , et al: Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J Intern Med 246:105-112, 1999.

51.

51. Dunstan DW , Mori TA , Puddey IA , et al: A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics. Thromb Haemost 81:367-372, 1999.

52.

52. Cahan MA , Killewich LA , Gardner AW : Enhancement of fibrinolysis in peripheral arterial occlusive disease with physical activity: A mechanism for reduction of cardiovascular events. Abstract at Society for Vascular Medicine and Biology Annual Meeting, June 2-3,1999, Washington, D.C.

53.

53. Killewich LA , Macko RF , Wiley LA , et al: Exercise enhances endogenous fibrinolysis in peripheral arterial occlusive disease. Circulation, submitted for publication.

54.

54. Hakim AA , Petrovitch H , Burchfiel CM , et al: Effects of walking on mortality among nonsmoking retired men. N Engl J Med 338:94-99, 1998.

55.

55. Friederich PW , Levi M , Biemond BJ , et al: Novel lowmolecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 96:916-921, 1997.